94 related articles for article (PubMed ID: 18203050)
1. Novel augmentation therapy with cilostazol for the geriatric major depressive disorder patient with deep white matter hyperintensities on T2-weighted brain MRI: a case report.
Takahashi K; Oshima A; Inoue K; Takeyoshi H; Fukuda M; Mikuni M
Pharmacopsychiatry; 2008 Jan; 41(1):37-9. PubMed ID: 18203050
[No Abstract] [Full Text] [Related]
2. [Augmentation therapy with cilostazol for the intractable geriatric major depressive disorder patients with deep white matter hyperintensities on T2-weighted brain MRI].
Takahashi K; Mikuni M
Seishin Shinkeigaku Zasshi; 2012; 114(3):297-302. PubMed ID: 22568064
[TBL] [Abstract][Full Text] [Related]
3. Hyperintensities on T2-weighted images in the basal ganglia of patients with major depression: cerebral perfusion and clinical implications.
Vardi N; Freedman N; Lester H; Gomori JM; Chisin R; Lerer B; Bonne O
Psychiatry Res; 2011 May; 192(2):125-30. PubMed ID: 21482458
[TBL] [Abstract][Full Text] [Related]
4. Brain white-matter hyperintensities and treatment outcome in major depressive disorder.
Iosifescu DV; Renshaw PF; Lyoo IK; Lee HK; Perlis RH; Papakostas GI; Nierenberg AA; Fava M
Br J Psychiatry; 2006 Feb; 188():180-5. PubMed ID: 16449707
[TBL] [Abstract][Full Text] [Related]
5. Imaging predictors of remission to anti-depressant medications in major depressive disorder.
Chi KF; Korgaonkar M; Grieve SM
J Affect Disord; 2015 Nov; 186():134-44. PubMed ID: 26233324
[TBL] [Abstract][Full Text] [Related]
6. The relationship of MRI subcortical hyperintensities to treatment response in a trial of sertraline in geriatric depressed outpatients.
Salloway S; Boyle PA; Correia S; Malloy PF; Cahn-Weiner DA; Schneider L; Krishnan KR; Nakra R
Am J Geriatr Psychiatry; 2002; 10(1):107-11. PubMed ID: 11790641
[TBL] [Abstract][Full Text] [Related]
7. Anatomical and functional correlates in major depressive disorder: the contribution of neuroimaging studies.
Rigucci S; Serafini G; Pompili M; Kotzalidis GD; Tatarelli R
World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):165-80. PubMed ID: 19670087
[TBL] [Abstract][Full Text] [Related]
8. Structural abnormality on brain magnetic resonance imaging in late-onset major depressive disorder.
Lin HF; Kuo YT; Chiang IC; Chen HM; Chen CS
Kaohsiung J Med Sci; 2005 Sep; 21(9):405-11. PubMed ID: 16248124
[TBL] [Abstract][Full Text] [Related]
9. White matter hyperintensities, medial temporal lobe atrophy, cortical atrophy, and response to electroconvulsive therapy in severely depressed elderly patients.
Oudega ML; van Exel E; Wattjes MP; Comijs HC; Scheltens P; Barkhof F; Eikelenboom P; de Craen AJ; Beekman AT; Stek ML
J Clin Psychiatry; 2011 Jan; 72(1):104-12. PubMed ID: 20816035
[TBL] [Abstract][Full Text] [Related]
10. Functional MRI findings, pharmacological treatment in major depression and clinical response.
Arnone D
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Apr; 91():28-37. PubMed ID: 30099082
[TBL] [Abstract][Full Text] [Related]
11. Duloxetine's effects in resting functional magnetic resonance imaging of first-episode, drug-naive major depressive disorder with panic disorder patients.
Lai CH
J Neuropsychiatry Clin Neurosci; 2011; 23(3):E10-1. PubMed ID: 21948903
[No Abstract] [Full Text] [Related]
12. A subtle grey-matter increase in first-episode, drug-naive major depressive disorder with panic disorder after 6 weeks' duloxetine therapy.
Lai CH; Hsu YY
Int J Neuropsychopharmacol; 2011 Mar; 14(2):225-35. PubMed ID: 20663271
[TBL] [Abstract][Full Text] [Related]
13. Duloxetine related effects of brain structure on a patient of major depressive disorder with panic disorder.
Lai CH
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):240-1. PubMed ID: 19833160
[No Abstract] [Full Text] [Related]
14. Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part I).
Iosifescu DV; Papakostas GI; Lyoo IK; Lee HK; Renshaw PF; Alpert JE; Nierenberg A; Fava M
Psychiatry Res; 2005 Dec; 140(3):291-9. PubMed ID: 16298109
[TBL] [Abstract][Full Text] [Related]
15. White matter hyperintensity progression and late-life depression outcomes.
Taylor WD; Steffens DC; MacFall JR; McQuoid DR; Payne ME; Provenzale JM; Krishnan KR
Arch Gen Psychiatry; 2003 Nov; 60(11):1090-6. PubMed ID: 14609884
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole monotherapy-related gray-matter growth in a patient with first-episode drug-naïve non-psychotic major depressive disorder.
Lai CH
J Neuropsychiatry Clin Neurosci; 2012; 24(3):E49-50. PubMed ID: 23037685
[No Abstract] [Full Text] [Related]
17. Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II).
Papakostas GI; Iosifescu DV; Renshaw PF; Lyoo IK; Lee HK; Alpert JE; Nierenberg AA; Fava M
Psychiatry Res; 2005 Dec; 140(3):301-7. PubMed ID: 16297603
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine's modest short-term influences in subcortical structures of first episode drug-naïve patients with major depressive disorder and panic disorder.
Lai CH; Wu YT
Psychiatry Res; 2011 Nov; 194(2):157-62. PubMed ID: 21820879
[TBL] [Abstract][Full Text] [Related]
19. T2-weighted image hyperintensities in major depression: focus on the basal ganglia.
Agid R; Levin T; Gomori JM; Lerer B; Bonne O
Int J Neuropsychopharmacol; 2003 Sep; 6(3):215-24. PubMed ID: 12974987
[TBL] [Abstract][Full Text] [Related]
20. Major depressive disorder with anger attacks and subcortical MRI white matter hyperintensities.
Iosifescu DV; Renshaw PF; Dougherty DD; Lyoo IK; Lee HK; Fraguas R; Cassano P; Nierenberg AA; Fava M
J Nerv Ment Dis; 2007 Feb; 195(2):175-8. PubMed ID: 17299307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
